Steven Vogl, MD
Medical Oncologist,
New York City
New York City
ESMO 2020 saw the presentation of early results from 2 double-blind, placebo-controlled trials examining adjuvant hormonal therapy for resected very high–risk, hormone receptor–positive breast cancer with cyclin dependent kinase (CDK) 4/6 inhibitors or placebo. One study, called PALLAS, using palbociclib (Ibrance, Pfizer), was closed early for futility, expecting never to achieve a positive result.1 The other, called MonarchE, using